Arvinas “announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of Chief Medical Officer and a member of the Executive Committee reporting to President and Chief Executive Officer John Houston, Ph.D. Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC(R) protein degrader programs in oncology and neuroscience.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARVN:
- Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas price target raised to $60 from $26 at Barclays
- Arvinas price target raised to $59 from $33 at Wedbush
- Arvinas VERITAC-2 trial timelines not changed, says Oppenheimer